Posted 12 February, 2024

Telomir Pharmaceuticals, Inc. IPO completed

IPO completed detected for ticker Nasdaq:TELO in a 424B1 filed on 12 February, 2024.

  This is the initial public offering of 1,000,000 shares of common stock, no par value, of Telomir Pharmaceuticals, Inc.  

Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Telomir Pharmaceuticals, Inc.
Health Care/Life Sciences • Pharmaceuticals
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. It focuses on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for human stem cells. The firm’s initial focus on treatments to inhibit the production of pro-inflammatory cytokines, such as IL-17, by oral administration of TELOMIR-1 as a therapeutic treatment for stem cells in situ. TELOMIR-1 is under investigation to provide a potential therapeutic intervention against age-related inflammatory conditions such as hemochromatosis, as well as for post-chemotherapy recovery, by interrupting and preventing the IL-17 induced inflammatory pathways that create the systemic imbalance of cellular metals. The company was founded on August 26, 2021 and is headquartered in Baltimore, MD.
Market Cap
View Company Details